7464-52-0

Basic information

• Product Name: 4-methoxy-N-(4-nitrophenyl)benzamide
• Synonyms: benzamide, 4-methoxy-N-(4-nitrophenyl)-
• CAS NO: 7464-52-0
• Molecular Formula: C₁₄H₁₂N₂O₄
• Molecular Weight: 272.2561
• Mol File: 7464-52-0.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 377.3°C at 760 mmHg
• Flash Point: 182°C
• Density: 1.333g/cm³
• Vapor Pressure: 6.8E-06mmHg at 25°C
• Refractive Index: 1.645
• CAS DataBase Reference: 4-methoxy-N-(4-nitrophenyl)benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-methoxy-N-(4-nitrophenyl)benzamide(7464-52-0)
• EPA Substance Registry System: 4-methoxy-N-(4-nitrophenyl)benzamide(7464-52-0)

Safety Data

• Hazardous Substances Data: 7464-52-0(Hazardous Substances Data)

Upstream product

• 100-07-2 4-methoxy-benzoyl chloride 
• 100-01-6 4-nitro-aniline 
• 38968-72-8 4-Methoxy-N-phenyl-benzimidoyl chloride 
• 7465-88-5 4-methoxy-N-phenylbenzamide 
• 62-53-3 aniline 
• 100-09-4 4-methoxybenzoic acid 
• 1516-60-5 4-nitrophenyl azide 
• 3424-93-9 4-methoxyphenylacetamide 
• 586-78-7 para-nitrophenyl bromide 
• 61166-15-2 1-(p-methoxybenzoyl)-3-methylimidazolium chloride 
• 98-95-3 nitrobenzene 
• 123-11-5 4-methoxy-benzaldehyde 

Downstream Products

• 1017572-85-8 (Z)-N-(1-(4-methoxyphenyl)-3-(trimethylsilyl)prop-2-ynylidene)-4-nitroaniline 
• 23600-43-3 N?(4?aminophenyl)?4?methoxybenzamide 
• 21010-34-4 4-methoxy-N-(4-nitrophenyl)benzothioamide 

Relevant articles and documents

Design, synthesis and molecular modeling study of certain VEGFR-2 inhibitors based on thienopyrimidne scaffold as cancer targeting agents

Different series of novel thieno [2,3-d]pyrimidine derivative (9a-d,10a-f,l,m and 15a-m) were designed, synthesized and evaluated for their ability to in vitro inhibit VEGFR-2 enzyme. Also, the cytotoxicity of the final compounds was tested against a panel of 60 different human cancer cell lines by NCI. The VEGFR-2 enzyme inhibitory results revealed that compounds 10d, 15d and 15 g are among the most active inhibitors with IC50 values of 2.5, 5.48 and 2.27 μM respectively, while compound 10a remarkably showed the highest cell growth inhibition with mean growth inhibition (GI) percent of 31.57%. It exhibited broad spectrum anti-proliferative activity against several NCI cell lines specifically on human breast cancer (T7-47D) and renal cancer (A498) cell lines of 85.5% and 77.65% inhibition respectively. To investigate the mechanistic aspects underlying the activity, further biological studies like flow cytometry cell cycle together with caspase-3 colorimetric assays were carried on compound 10a. Flow cytometric analysis on both MCV-7 and PC-3 cancer cells revealed that it induced cell-cycle arrest in the G0-G1phase and reinforced apoptosis via activation of caspase-3. Furthermore, molecular modeling studies have been carried out to gain further understanding of the binding mode in the active site of VEGFR-2 enzyme and predict pharmacokinetic properties of all the synthesized inhibitors.

Diarylurea histone deacetylation enzyme inhibitor

The invention belongs to the field of medical chemistry and particularly relates to a diarylurea histone deacetylation enzyme inhibitor, a medicine composition containing the histone deacetylation enzyme inhibitor, application of the inhibitor to preparat

4-substituted anilinoquinazoline derivatives, and preparation method and application thereof

The invention discloses novel 4-substituted anilinoquinazoline derivatives or pharmaceutically acceptable salts thereof, or polymorphic substances, solvates or stereomers of the 4-substituted anilinoquinazoline derivatives, and a preparation method and application thereof. The 4-substituted anilinoquinazoline compounds have favorable inhibition activities for EGFR and VEGFR-2 in a biological test and have obvious effects in an in-vitro anti-human tumor cell proliferation activity test.